Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication -: A randomized controlled trial (MACLOR study)
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication -: A randomized controlled trial (MACLOR study)
复制标题
DOI：
10.1001/archinte.162.2.153
复制
发表时间：
2002-01-28
影响因子：
--
通讯作者：
Klotz, U
中科院分区：
文献类型：
--
作者：
Treiber, G;Wittig, J;Klotz, U
背景：与标准的1周三联治疗相比，短期治疗对特定患者根除幽门螺杆菌可能在成本、依从性和不良反应方面具有优势。方法：为确定新型短期四联疗法根除幽门螺杆菌成功率及其影响因素，将243例幽门螺杆菌阳性患者根据年龄、吸烟状况及诊断情况随机分为3个治疗方案，其中1个治疗方案为5天，使用3种抗生素（阿莫西林，1 g，每日2次[bid]；克拉霉素，250 mg bid；甲硝唑，400 mg bid）和兰索拉唑(30 mg bid；[参考治疗])或盐酸雷尼替丁（bid 300 mg [R5]），或同样的3天抗生素-兰索拉唑联合治疗（L3），前用兰索拉唑2天。结果：共有234例患者完成了研究。在意向治疗的基础上，确认幽门螺杆菌根除率为86.4%:L5组为89.2%，L3组为81.2%，R5组为88.8%；差异不显著。多元logistic回归分析显示，年龄越小(
Background: Short-term therapies for eradicating Helicobacter pylori in selected patients might offer advantages in terms of costs, compliance, and adverse effects in contrast to standard I-week triple therapy.Methods: To determine eradication success and influencing factors in a new short-term quadruple therapy, a total of 243 patients positive for H pylori were randomly assigned to I of 3 regimens according to age, smoking status, and diagnosis: a 5-day treatment with 3 antibiotics (amoxicillin, 1 g twice daily [bid]; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid) and lansoprazole (30 mg bid [L5; reference treatment]) or ranitidine hydrochloride (300 mg bid [R5]), or the same 3-day antibiotic-lansoprazole combination (L3) with a 2-day pretreatment with lansoprazole.Results: A total of 234 patients completed the study. On an intention-to-treat basis, overall eradication of H pylori was confirmed in 86.4%: 89.2% in the L5 group vs 81.2% in the L3 group vs 88.8% in the R5 group; differences were not significant. Multiple logistic regression analysis showed that younger age (